» Articles » PMID: 12927291

Clinicopathological Study of Undifferentiated Carcinoma of the Parotid Gland

Overview
Date 2003 Aug 21
PMID 12927291
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Undifferentiated carcinoma of the salivary gland is a rare malignant tumor, and is difficult to distinguish from other poorly differentiated types of carcinoma or sarcoma. The present study investigated clinical and pathological characteristics for undifferentiated carcinoma of the parotid gland.

Patients And Methods: Forty-four patients with previously untreated carcinoma of the major salivary glands were treated at our institution between 1986 and 1999. Of these, five patients (two males, three females) were diagnosed with undifferentiated carcinoma of the parotid gland and treated. For histological reinvestigation, multislices of resected specimens were made and diagnosed.

Results: Although all patients were treated by radical surgery (more than subtotal parotidectomy), all died of distant metastasis, including two patients with locoregional relapse. Tumors in these two patients included a small portion of poorly differentiated epidermoid or mucoepidermoid carcinoma. The remaining three patients did not show any differentiated portions, and histological findings demonstrated heterogeneous patterns of lymphoepithelial carcinoma, small cell carcinoma and unclassified (a pattern of malignant hemangiopericytoma), respectively.

Conclusions: Investigation using multislice sections is needed to diagnose undifferentiated carcinoma of the salivary glands. Regarding prognosis, carcinoma that is too poorly differentiated but including slightly-differentiated portions should be considered undifferentiated carcinoma. All patients died of distant metastasis despite radical surgery, suggesting that chemotherapy is needed to improve patient outcomes.

Citing Articles

Lymphoepithelial Carcinoma of Salivary Gland EBV-association in Endemic versus Non-Endemic Patients: A Report of 16 Cases.

Whaley R, Carlos R, Bishop J, Rooper L, Thompson L Head Neck Pathol. 2020; 14(4):1001-1012.

PMID: 32462279 PMC: 7669917. DOI: 10.1007/s12105-020-01172-w.


Malignant Transformation of Parotid Gland Non-sebaceous Lymphadenoma: Case Report and Review of Literature.

Kara H, Sonmez S, Bagbudar S, Gulluoglu M, Basaran B Head Neck Pathol. 2020; 14(4):1123-1128.

PMID: 31997132 PMC: 7669958. DOI: 10.1007/s12105-020-01133-3.


The Three P's: Parotid, PD-L1, and Pembrolizumab.

Wiggins A, Arter Z, Kerns T Case Rep Oncol Med. 2019; 2019:2305315.

PMID: 31308983 PMC: 6594310. DOI: 10.1155/2019/2305315.


Neuroendocrine neoplasms of the head and neck: some suggestions for the new WHO classification of head and neck tumors.

Xu B, Chetty R, Perez-Ordonez B Head Neck Pathol. 2014; 8(1):24-32.

PMID: 24595420 PMC: 3950384. DOI: 10.1007/s12105-014-0531-y.


Prognostic value of proliferating cell nuclear antigen in parotid gland cancer.

Stenner M, Demgensky A, Molls C, Hardt A, Luers J, Grosheva M Eur Arch Otorhinolaryngol. 2011; 269(4):1225-32.

PMID: 21874325 DOI: 10.1007/s00405-011-1740-6.